Table 1.
Data of Patients
| No. | Sex | Age (yr) | Site | BMI (kg/m2) | Anticoagulant | Interval between TKA and hemarthrosis (wk) | Aspiration | Angio & embolization | Surgical exploration | Results |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 65 | L | 26.3 | - | 70 | 7 | Yes | Yes | Improved |
| 2 | F | 68 | R | 25.4 | - | 238 | 4 | No | No | Improved |
| 3 | F | 70 | R | 26.2 | Aspirin | 310 | 3 | No | No | Improved |
| 4 | F | 71 | L | 27.5 | Arixtra (fondaparinux sodium) | 54 | 2 | No | No | Improved |
| 5 | F | 70 | L | 24.5 | - | 67 | 4 | No | No | Improved |
| 6 | F | 66 | R | 36.7 | Aspirin | 158 | 4 | No | No | Improved |
| 7 | F | 71 | R | 29.9 | Aspirin | 404 | 3 | No | No | Improved |
| 8 | F | 67 | R | 25.4 | Arixtra (fondaparinux sodium) & Ginkgo biloba extract | 98 | 5 | Yes | No | Improved |
| 9 | M | 76 | R | 22.8 | Wafarin | 2 | 2 | No | No | Improved |
| 10 | F | 61 | R | 23.8 | Arixtra (fondaparinux sodium) | 25 | 2 | No | No | Improved |
| 11 | F | 75 | L | 27.2 | Arixtra (rivaroxaban) | 166 | 2 | No | No | Improved |
| 12 | F | 63 | R | 25.4 | Rivaroxaban | 139 | 2 | No | No | Improved |
| 13 | M | 65 | L | 28.0 | Aspirin | 2 | 10 | Yes | Yes | Improved after another embolization |
| 14 | F | 70 | L | 22.1 | - | 2 | 2 | No | No | Improved |
| 15 | M | 76 | R | 21.2 | - | 8 | 4 | No | No | Improved |
| 16 | F | 76 | L | 22.0 | Arixtra (fondaparinux sodium) | 65 | 2 | No | No | Improved |
| 17 | F | 65 | L | 32 | Arixtra (fondaparinux sodium) & aspirin | 79 | 2 | No | No | Improved |
BMI: body mass index, TKA: total knee arthroplasty, L: left, R: right.